Ghislain, P.D.
454  results:
Search for persons X
?
1

Secukinumab demonstrated sustained retention, effectiveness..:

Augustin, M. ; Sator, P.G. ; von Kiedrowski, R....
Journal of the European Academy of Dermatology and Venereology.  36 (2022)  10 - p. 1796-1804 , 2022
 
?
2

Systemic treatment of children and adolescents with atopic ..:

de Graaf, M. ; Janmohamed, S.R. ; Schuttelaar, M.L.A....
Journal of the European Academy of Dermatology and Venereology.  36 (2022)  11 - p. 2153-2165 , 2022
 
?
3

Improvement in Hidradenitis Suppurativa and quality of life..:

Hafner, A. ; Ghislain, P.D. ; Kovács, R....
Journal of the European Academy of Dermatology and Venereology.  35 (2021)  11 - p. 2277-2284 , 2021
 
?
4

Efficacité et tolérance du baricitinib (bari) associé à des..:

Bieber, T. ; Reich, K. ; Paul, C....
Annales de Dermatologie et de Vénéréologie.  147 (2020)  12 - p. A121-A122 , 2020
 
?
5

Profil de sécurité à long terme du tildrakizumab : Incidenc..:

Reich, K. ; Ghislain, P.-D. ; Schoenenberger, A..
Annales de Dermatologie et de Vénéréologie.  147 (2020)  12 - p. A349-A350 , 2020
 
?
6

Practical recommendations for systemic treatment in psorias..:

Lambert, J.L.W. ; Segaert, S. ; Ghislain, P.D....
Journal of the European Academy of Dermatology and Venereology.  34 (2020)  8 - p. 1654-1665 , 2020
 
?
7

Effectiveness and short‐term (16‐week) tolerance of guselku..:

Fougerousse, A.‐C. ; Ghislain, P.‐D. ; Reguiai, Z....
Journal of the European Academy of Dermatology and Venereology.  34 (2020)  10 - p. , 2020
 
?
8

Efficacité et tolérance à court terme (16 semaines) du guse..:

Fougerousse, A.-C. ; Ghislain, P.-D. ; Reguiai, Z....
Annales de Dermatologie et de Vénéréologie.  147 (2020)  12 - p. A326-A327 , 2020
 
?
9

Real‐life effectiveness and short‐term (16‐week) tolerance ..:

Benhadou, F. ; Ghislain, P.D. ; Guiot, F....
Journal of the European Academy of Dermatology and Venereology.  34 (2020)  12 - p. , 2020
 
?
10

A Belgian consensus on the definition of a treat‐to‐target ..:

Grine, L. ; de la Brassinne, M. ; Ghislain, P.‐D....
Journal of the European Academy of Dermatology and Venereology.  34 (2020)  4 - p. 676-684 , 2020
 
?
11

Ixekizumab improves secondary lesional signs, pain and sexu..:

Merola, J.F. ; Ghislain, P.‐D. ; Dauendorffer, J.N....
Journal of the European Academy of Dermatology and Venereology.  34 (2020)  6 - p. 1257-1262 , 2020
 
?
12

Practical recommendations for systemic treatment in psorias..:

Lambert, J.L.W. ; Segaert, S. ; Ghislain, P.D....
Journal of the European Academy of Dermatology and Venereology.  34 (2020)  9 - p. 1914-1923 , 2020
 
?
13

Sustained long‐term efficacy and safety of adalimumab in pa..:

Thaçi, D. ; Papp, K. ; Marcoux, D....
British Journal of Dermatology.  181 (2019)  6 - p. 1177-1189 , 2019
 
?
14

Development of a Highly Granular Silicon-Tungsten ECAL for ..:

Sudo, Y. ; Kawagoe, K. ; Suehara, T....
Nuclear and Particle Physics Proceedings.  273-275 (2016)  - p. 2554-2556 , 2016
 
?
15

Beam test performance of the SKIROC2 ASIC:

Amjad, M.S. ; Anduze, M. ; Augustin, J.-E....
Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment.  778 (2015)  - p. 78-84 , 2015
 
1-15